"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford, chairman and CEO, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott Delivers Better-than-Expected Q4 Earnings
- Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
- Notable companies reporting before tomorrow’s open
- Abbott price target raised to $110 from $105 at Mizuho
- Pharma Industry Could Benefit from Rise in Medicine Spending
